奥泰生物
(688606)
| 流通市值：55.41亿 | | | 总市值：55.41亿 |
| 流通股本：7928.09万 | | | 总股本：7928.09万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 618,025,472.14 | 396,503,367.26 | 199,920,896.28 | 754,696,888.86 |
| 营业收入 | 618,025,472.14 | 396,503,367.26 | 199,920,896.28 | 754,696,888.86 |
| 二、营业总成本 | 425,103,891.99 | 272,928,388.15 | 144,138,319.97 | 592,083,574.56 |
| 营业成本 | 273,429,699.73 | 178,394,130.3 | 99,702,324.24 | 386,540,797.7 |
| 税金及附加 | 4,774,025.45 | 3,578,736.62 | 2,049,793.49 | 7,037,005.11 |
| 销售费用 | 41,885,987.45 | 30,047,771.37 | 10,813,141.14 | 69,285,218.73 |
| 管理费用 | 45,636,701.66 | 30,135,503.89 | 13,493,416.42 | 66,586,762.42 |
| 研发费用 | 71,504,941.41 | 49,158,799.28 | 23,156,697.04 | 121,169,279.46 |
| 财务费用 | -12,127,463.71 | -18,386,553.31 | -5,077,052.36 | -58,535,488.86 |
| 其中:利息费用 | 366,181.49 | 260,841.93 | 132,558.32 | 1,448,673.48 |
| 其中:利息收入 | 17,858,437.69 | 17,477,200.31 | 5,365,092.08 | 35,618,333.76 |
| 加:公允价值变动收益 | 22,550,628.77 | 12,656,702.03 | 3,363,643.08 | 32,668,473.1 |
| 加:投资收益 | 11,590,830.28 | 9,206,166.83 | 4,204,435.81 | 8,634,776.34 |
| 资产处置收益 | 3,480,365.44 | 3,342,244.85 | -6,081.72 | -419,217.85 |
| 资产减值损失(新) | -7,314,634.97 | -8,386,371.65 | -5,444,901.01 | 5,601,209.45 |
| 信用减值损失(新) | -13,940,234.76 | -12,262,428 | -11,367,660.48 | -11,227,697.68 |
| 其他收益 | 17,493,941.76 | 13,918,354.85 | 796,950.38 | 13,710,450.52 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 226,782,476.67 | 142,049,648.02 | 47,328,962.37 | 211,581,308.18 |
| 加:营业外收入 | 179,812.1 | 179,742.51 | 100,000.17 | 24,082.7 |
| 减:营业外支出 | 3,644,577.57 | 3,080,758.59 | 271,695.4 | 14,166,640.65 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 223,317,711.2 | 139,148,631.94 | 47,157,267.14 | 197,438,750.23 |
| 减:所得税费用 | 25,772,550.07 | 15,614,052.2 | 2,512,937.47 | 17,158,142.06 |
| 六、净利润 | 197,545,161.13 | 123,534,579.74 | 44,644,329.67 | 180,280,608.17 |
| 持续经营净利润 | 197,545,161.13 | 123,534,579.74 | 44,644,329.67 | 180,280,608.17 |
| 归属于母公司股东的净利润 | 197,526,404.8 | 123,879,409.14 | 44,788,913.62 | 180,576,190.21 |
| 少数股东损益 | 18,756.33 | -344,829.4 | -144,583.95 | -295,582.04 |
| (一)基本每股收益 | 2.49 | 1.56 | 0.56 | 2.28 |
| (二)稀释每股收益 | 2.49 | 1.56 | 0.56 | 2.28 |
| 八、其他综合收益 | -1,478,128.56 | 648,531.96 | 151,351.08 | 2,367,625.72 |
| 归属于母公司股东的其他综合收益 | -1,478,414.22 | 637,986.09 | 144,607.76 | 2,363,130.17 |
| 九、综合收益总额 | 196,067,032.57 | 124,183,111.7 | 44,795,680.75 | 182,648,233.89 |
| 归属于母公司股东的综合收益总额 | 196,047,990.58 | 124,517,395.23 | 44,933,521.38 | 182,939,320.38 |
| 归属于少数股东的综合收益总额 | 19,041.99 | -334,283.53 | -137,840.63 | -291,086.49 |
| 公告日期 | 2024-10-31 | 2024-08-31 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |